Login to Your Account

Deals And M&A NEWS

Epirus Pharmaceuticals Inc.'s all-stock takeover of Zalicus Inc., disclosed on the same day that Epirus put the wraps on a $36 million series B round, will add early stage pain drug candidates to its pipeline of biosimilars and immediately put some joy back into Zalicus' shares.

SHANGHAI – 2013 was another banner year for biopharmaceutical licensing deals in China, with inbound agreements continuing to grow and outbound transactions showing up noticeably for the first time.
Neostem Inc. set its sights on the hot cancer immunotherapy market with an agreement to acquire California Stem Cell Inc. (CSC) through a stock transaction. The New York-based cell therapy company moves melapuldencel-T, an autologous stem cell immune-based therapy, to the head of the class and takes on the challenge of a phase III trial with the CSC buy.
More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: